Literature DB >> 19560512

Mental slowness and executive dysfunctions in patients with metabolic syndrome.

Bàrbara Segura1, María Angeles Jurado, Núria Freixenet, Carlota Albuin, Jesús Muniesa, Carme Junqué.   

Abstract

Metabolic Syndrome is a cluster of vascular risk factors which has been related to dementia and cognitive decline. The aim of this study was to describe the neuropsychological profile of metabolic syndrome patients. An extensive neuropsychological protocol was administered to 55 patients and 35 controls assessing memory, executive, visuoperceptual and visuoconstructive functions, language and speed of processing. There were differences between groups in speed of processing and some executive functions after controlling for the influences of education and gender. The results suggest that metabolic syndrome may be a prodromal state of vascular cognitive impairment.

Entities:  

Mesh:

Year:  2009        PMID: 19560512     DOI: 10.1016/j.neulet.2009.06.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  33 in total

Review 1.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Functional MR imaging evidence of altered functional activation in metabolic syndrome.

Authors:  K F Hoth; M M Gonzales; T Tarumi; S C Miles; H Tanaka; A P Haley
Journal:  AJNR Am J Neuroradiol       Date:  2010-12-23       Impact factor: 3.825

Review 3.  Impact of metabolic syndrome on cognition and brain: a selected review of the literature.

Authors:  Kathy F Yates; Victoria Sweat; Po Lai Yau; Michael M Turchiano; Antonio Convit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

4.  Current serum lipoprotein levels and FMRI response to working memory in midlife.

Authors:  Mitzi M Gonzales; Takashi Tarumi; Danielle E Eagan; Hirofumi Tanaka; Fedora O Biney; Andreana P Haley
Journal:  Dement Geriatr Cogn Disord       Date:  2011-04-13       Impact factor: 2.959

Review 5.  White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging.

Authors:  Freddy J Alfaro; Anna Gavrieli; Patricia Saade-Lemus; Vasileios-Arsenios Lioutas; Jagriti Upadhyay; Vera Novak
Journal:  Metabolism       Date:  2017-09-08       Impact factor: 8.694

6.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Course and etiology of dysexecutive MCI in a community sample.

Authors:  Edward D Huey; Jennifer J Manly; Ming-X Tang; Nicole Schupf; Adam M Brickman; Masood Manoochehri; Jesse Mez; Charles DeCarli; Davangere P Devanand; Richard Mayeux
Journal:  Alzheimers Dement       Date:  2013-02-27       Impact factor: 21.566

8.  White matter fractional anisotropy is related to processing speed in metabolic syndrome patients: a case-control study.

Authors:  Bàrbara Segura; María Angeles Jurado; Núria Freixenet; Núria Bargalló; Carme Junqué; Adrià Arboix
Journal:  BMC Neurol       Date:  2010-07-27       Impact factor: 2.474

9.  Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study.

Authors:  M Schuur; P Henneman; J C van Swieten; M C Zillikens; I de Koning; A C J W Janssens; J C M Witteman; Y S Aulchenko; R R Frants; B A Oostra; K Willems van Dijk; C M van Duijn
Journal:  Eur J Epidemiol       Date:  2010-06-29       Impact factor: 8.082

10.  Dietary advanced glycation end products are associated with decline in memory in young elderly.

Authors:  Rebecca K West; Erin Moshier; Irit Lubitz; James Schmeidler; James Godbold; Weijing Cai; Jaime Uribarri; Helen Vlassara; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  Mech Ageing Dev       Date:  2014-07-15       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.